| Title |
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
|
|---|---|
| Published in |
Clinical Drug Investigation, May 2018
|
| DOI | 10.1007/s40261-018-0655-z |
| Pubmed ID | |
| Authors |
Ekaterini C. Tampaki, Athanasios Tampakis, Constantinos E. Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T. Trafalis |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 14% |
| Student > Bachelor | 9 | 14% |
| Student > Ph. D. Student | 8 | 12% |
| Professor | 4 | 6% |
| Researcher | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 20 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 34% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Nursing and Health Professions | 4 | 6% |
| Engineering | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 20 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2018.
All research outputs
#23,391,126
of 26,017,215 outputs
Outputs from Clinical Drug Investigation
#963
of 1,056 outputs
Outputs of similar age
#304,703
of 344,699 outputs
Outputs of similar age from Clinical Drug Investigation
#9
of 10 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,056 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,699 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.